JPWO2020198266A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020198266A5 JPWO2020198266A5 JP2021557333A JP2021557333A JPWO2020198266A5 JP WO2020198266 A5 JPWO2020198266 A5 JP WO2020198266A5 JP 2021557333 A JP2021557333 A JP 2021557333A JP 2021557333 A JP2021557333 A JP 2021557333A JP WO2020198266 A5 JPWO2020198266 A5 JP WO2020198266A5
- Authority
- JP
- Japan
- Prior art keywords
- independently
- pharmaceutically acceptable
- acceptable salt
- och2c
- conditions
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 14
- 150000003839 salts Chemical class 0.000 claims 14
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 10
- 125000001424 substituent group Chemical group 0.000 claims 10
- 201000010099 disease Diseases 0.000 claims 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 8
- 125000003545 alkoxy group Chemical group 0.000 claims 7
- 125000000217 alkyl group Chemical group 0.000 claims 7
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 6
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 claims 5
- 125000004093 cyano group Chemical group *C#N 0.000 claims 5
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 4
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 claims 4
- 206010028980 Neoplasm Diseases 0.000 claims 4
- 229910052736 halogen Inorganic materials 0.000 claims 4
- 150000002367 halogens Chemical class 0.000 claims 4
- 125000004076 pyridyl group Chemical group 0.000 claims 4
- 210000001635 urinary tract Anatomy 0.000 claims 4
- 125000004767 (C1-C4) haloalkoxy group Chemical group 0.000 claims 3
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 claims 3
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 3
- 229910052801 chlorine Inorganic materials 0.000 claims 3
- 208000019425 cirrhosis of liver Diseases 0.000 claims 3
- 125000001475 halogen functional group Chemical group 0.000 claims 3
- 208000006454 hepatitis Diseases 0.000 claims 3
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 3
- 125000001624 naphthyl group Chemical group 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 230000002062 proliferating effect Effects 0.000 claims 3
- 206010016654 Fibrosis Diseases 0.000 claims 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 2
- 206010027476 Metastases Diseases 0.000 claims 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 2
- 208000002158 Proliferative Vitreoretinopathy Diseases 0.000 claims 2
- 206010038934 Retinopathy proliferative Diseases 0.000 claims 2
- 230000002159 abnormal effect Effects 0.000 claims 2
- 206010064930 age-related macular degeneration Diseases 0.000 claims 2
- 229910052794 bromium Inorganic materials 0.000 claims 2
- 229910052731 fluorine Inorganic materials 0.000 claims 2
- 208000027866 inflammatory disease Diseases 0.000 claims 2
- 208000017169 kidney disease Diseases 0.000 claims 2
- 210000004185 liver Anatomy 0.000 claims 2
- 208000002780 macular degeneration Diseases 0.000 claims 2
- 201000000050 myeloid neoplasm Diseases 0.000 claims 2
- 208000021971 neovascular inflammatory vitreoretinopathy Diseases 0.000 claims 2
- 230000006785 proliferative vitreoretinopathy Effects 0.000 claims 2
- 208000003120 Angiofibroma Diseases 0.000 claims 1
- 208000031104 Arterial Occlusive disease Diseases 0.000 claims 1
- 206010054793 Arterial fibrosis Diseases 0.000 claims 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 1
- 208000009299 Benign Mucous Membrane Pemphigoid Diseases 0.000 claims 1
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 claims 1
- 206010008111 Cerebral haemorrhage Diseases 0.000 claims 1
- 206010008909 Chronic Hepatitis Diseases 0.000 claims 1
- 208000032544 Cicatrix Diseases 0.000 claims 1
- 206010012689 Diabetic retinopathy Diseases 0.000 claims 1
- 206010017943 Gastrointestinal conditions Diseases 0.000 claims 1
- 208000018522 Gastrointestinal disease Diseases 0.000 claims 1
- 208000010412 Glaucoma Diseases 0.000 claims 1
- 206010019663 Hepatic failure Diseases 0.000 claims 1
- 206010020751 Hypersensitivity Diseases 0.000 claims 1
- 208000003618 Intervertebral Disc Displacement Diseases 0.000 claims 1
- 208000007766 Kaposi sarcoma Diseases 0.000 claims 1
- 208000012192 Mucous membrane pemphigoid Diseases 0.000 claims 1
- 208000000693 Neurogenic Urinary Bladder Diseases 0.000 claims 1
- 206010029279 Neurogenic bladder Diseases 0.000 claims 1
- 206010034277 Pemphigoid Diseases 0.000 claims 1
- 206010035664 Pneumonia Diseases 0.000 claims 1
- 208000004403 Prostatic Hyperplasia Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 206010039710 Scleroderma Diseases 0.000 claims 1
- 201000009594 Systemic Scleroderma Diseases 0.000 claims 1
- 206010042953 Systemic sclerosis Diseases 0.000 claims 1
- 231100000354 acute hepatitis Toxicity 0.000 claims 1
- 230000001476 alcoholic effect Effects 0.000 claims 1
- 208000026935 allergic disease Diseases 0.000 claims 1
- 230000033115 angiogenesis Effects 0.000 claims 1
- 208000021328 arterial occlusion Diseases 0.000 claims 1
- 210000004556 brain Anatomy 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 206010008118 cerebral infarction Diseases 0.000 claims 1
- 208000026106 cerebrovascular disease Diseases 0.000 claims 1
- 201000010002 cicatricial pemphigoid Diseases 0.000 claims 1
- 230000007882 cirrhosis Effects 0.000 claims 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 206010013990 dysuria Diseases 0.000 claims 1
- 208000030533 eye disease Diseases 0.000 claims 1
- 230000004761 fibrosis Effects 0.000 claims 1
- 238000001914 filtration Methods 0.000 claims 1
- 210000002216 heart Anatomy 0.000 claims 1
- 230000002440 hepatic effect Effects 0.000 claims 1
- 231100000283 hepatitis Toxicity 0.000 claims 1
- 230000009610 hypersensitivity Effects 0.000 claims 1
- 230000001771 impaired effect Effects 0.000 claims 1
- 210000003734 kidney Anatomy 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 208000019423 liver disease Diseases 0.000 claims 1
- 208000007903 liver failure Diseases 0.000 claims 1
- 231100000835 liver failure Toxicity 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 230000009401 metastasis Effects 0.000 claims 1
- 230000027939 micturition Effects 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 208000004296 neuralgia Diseases 0.000 claims 1
- 208000021722 neuropathic pain Diseases 0.000 claims 1
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 claims 1
- 210000000056 organ Anatomy 0.000 claims 1
- 210000000496 pancreas Anatomy 0.000 claims 1
- 230000007170 pathology Effects 0.000 claims 1
- 230000010412 perfusion Effects 0.000 claims 1
- 208000033808 peripheral neuropathy Diseases 0.000 claims 1
- 208000007232 portal hypertension Diseases 0.000 claims 1
- 208000005069 pulmonary fibrosis Diseases 0.000 claims 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 claims 1
- 201000002793 renal fibrosis Diseases 0.000 claims 1
- 231100000241 scar Toxicity 0.000 claims 1
- 230000037387 scars Effects 0.000 claims 1
- 230000028327 secretion Effects 0.000 claims 1
- 210000003491 skin Anatomy 0.000 claims 1
- 206010062261 spinal cord neoplasm Diseases 0.000 claims 1
- 208000005198 spinal stenosis Diseases 0.000 claims 1
- 238000001356 surgical procedure Methods 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962823684P | 2019-03-26 | 2019-03-26 | |
| US62/823,684 | 2019-03-26 | ||
| PCT/US2020/024548 WO2020198266A1 (en) | 2019-03-26 | 2020-03-25 | Small molecule inhibitors of galectin-3 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2022527075A JP2022527075A (ja) | 2022-05-30 |
| JP2022527075A5 JP2022527075A5 (https=) | 2023-03-16 |
| JPWO2020198266A5 true JPWO2020198266A5 (https=) | 2023-03-16 |
| JP7478165B2 JP7478165B2 (ja) | 2024-05-02 |
Family
ID=70293127
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021557333A Active JP7478165B2 (ja) | 2019-03-26 | 2020-03-25 | ガレクチン－３の低分子阻害剤 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US12275719B2 (https=) |
| EP (1) | EP3947407B1 (https=) |
| JP (1) | JP7478165B2 (https=) |
| KR (1) | KR20210143255A (https=) |
| CN (1) | CN113727988A (https=) |
| ES (1) | ES2984075T3 (https=) |
| WO (1) | WO2020198266A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20230104190A (ko) * | 2020-11-02 | 2023-07-07 | 이도르시아 파마슈티컬스 리미티드 | 갈렉틴-3 억제 2-히드록시시클로알칸-1-카르바모일 유도체 |
| JP2024501010A (ja) * | 2020-12-28 | 2024-01-10 | ガレクト バイオテック エービー | ガレクチンに対する新規ガラクトシド阻害剤 |
| WO2023118267A1 (en) * | 2021-12-22 | 2023-06-29 | Galecto Biotech Ab | Novel galactoside inhibitor of galectins |
| WO2026002250A1 (zh) * | 2024-06-28 | 2026-01-02 | 上海济煜医药科技股份有限公司 | 四唑基取代的吡喃半乳糖苷衍生物及其制备方法和应用 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE0401301D0 (sv) * | 2004-05-21 | 2004-05-21 | Forskarpatent I Syd Ab | Novel 3-triazolyl-galactoside inhibitors of galectins |
| SE0401300D0 (sv) | 2004-05-21 | 2004-05-21 | Forskarpatent I Syd Ab | Novel Galactoside Inhibitors of Galectins |
| US9021050B2 (en) | 2012-08-31 | 2015-04-28 | Yume, Inc. | Network service system and method with off-heap caching |
| US8828971B2 (en) | 2012-10-10 | 2014-09-09 | Galectin Therapeutics, Inc. | Galactose-pronged carbohydrate compounds for the treatment of diabetic nephropathy and associated disorders |
| JP2015535233A (ja) | 2012-10-31 | 2015-12-10 | ガレクト・バイオテック・エイビイ | ガレクチン−３のガラクトシド阻害剤及び肺線維症のためのその使用 |
| JP6904906B2 (ja) * | 2015-01-30 | 2021-07-21 | ガレクト・バイオテック・エイビイ | ガレクチンの新規なガラクトシド阻害剤 |
| JP6844991B2 (ja) | 2015-11-10 | 2021-03-17 | サンコ テキスタイル イスレットメレリ サン ベ ティク エーエスＳａｎｋｏ Ｔｅｋｓｔｉｌ Ｉｓｌｅｔｍｅｌｅｒｉ Ｓａｎ． Ｖｅ Ｔｉｃ． Ａ．Ｓ． | ジッパーを有する伸縮性衣類の製法 |
| CA3025867A1 (en) * | 2016-07-12 | 2018-01-18 | Galecto Biotech Ab | Alpha-d-galactoside inhibitors of galectins |
| CA3062648A1 (en) * | 2017-05-12 | 2018-11-15 | Galectin Sciences, Llc | Compounds for the prevention and treatment of diseases and the use thereof |
| WO2019067702A1 (en) | 2017-09-27 | 2019-04-04 | Bristol-Myers Squibb Company | INHIBITORS WITH SMALL MOLECULES OF GALECTIN-3 |
-
2020
- 2020-03-25 EP EP20719877.1A patent/EP3947407B1/en active Active
- 2020-03-25 ES ES20719877T patent/ES2984075T3/es active Active
- 2020-03-25 JP JP2021557333A patent/JP7478165B2/ja active Active
- 2020-03-25 CN CN202080030355.9A patent/CN113727988A/zh active Pending
- 2020-03-25 US US17/439,845 patent/US12275719B2/en active Active
- 2020-03-25 KR KR1020217034150A patent/KR20210143255A/ko active Pending
- 2020-03-25 WO PCT/US2020/024548 patent/WO2020198266A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020510664A5 (https=) | ||
| JP2016517432A5 (https=) | ||
| CN115734966A (zh) | 杂环化合物及其用途 | |
| JP2021527102A5 (https=) | ||
| JP2018519357A5 (https=) | ||
| JP2019034943A5 (https=) | ||
| JP2017505790A5 (https=) | ||
| JP7656669B2 (ja) | マトリックスメタロプロテイナーゼ（ｍｍｐ）阻害剤及びその使用方法 | |
| RU2022108080A (ru) | Ингибиторы интегрина avb6 | |
| JP2021502387A5 (https=) | ||
| JP2014193925A5 (https=) | ||
| JP2014015465A5 (https=) | ||
| JP2015509098A5 (https=) | ||
| JP2014531441A5 (https=) | ||
| JPWO2019126085A5 (https=) | ||
| JP2019529359A5 (https=) | ||
| JPWO2020210308A5 (https=) | ||
| JPWO2019126086A5 (https=) | ||
| CA2796826A1 (en) | Bifunctional quinoline derivatives | |
| JP2006513221A5 (https=) | ||
| JP2018525425A5 (https=) | ||
| JP2021528451A5 (https=) | ||
| JP2017509694A5 (https=) | ||
| JP2017536342A5 (https=) | ||
| JPWO2020198266A5 (https=) |